CR10032A - Preparación sólida - Google Patents
Preparación sólidaInfo
- Publication number
- CR10032A CR10032A CR10032A CR10032A CR10032A CR 10032 A CR10032 A CR 10032A CR 10032 A CR10032 A CR 10032A CR 10032 A CR10032 A CR 10032A CR 10032 A CR10032 A CR 10032A
- Authority
- CR
- Costa Rica
- Prior art keywords
- insulin sensitizer
- solid preparation
- active ingredient
- coated
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención pretende proporcionar una preparación sólida que contiene un sensibilizador de insulina y un ingrediente activo distinto de un sensibilizador de insulina, y exhibe comportamientode disolución de un sensibilizador de insulina similar al de un sensibilizador de insulina proveniente de "una preparación sólida que solo contiene un sensibilizador de insulina como ingrediente activo". La preparación sólida comprende "una parte que contiene partículas recubiertas en donde las partículas que contienen un sensibilizador de insulina están recubiertas con lactosa o un alcohol de azúcar" y "una parte que contiene un ingrediente activo distinto de un sensibilizador de insulina".
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005370375 | 2005-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10032A true CR10032A (es) | 2008-10-03 |
Family
ID=37951491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10032A CR10032A (es) | 2005-12-22 | 2008-05-30 | Preparación sólida |
Country Status (24)
Country | Link |
---|---|
US (1) | US8071130B2 (es) |
EP (1) | EP1962811B1 (es) |
JP (1) | JP5179363B2 (es) |
KR (1) | KR20080080126A (es) |
CN (1) | CN101384251B (es) |
AR (1) | AR058605A1 (es) |
AU (1) | AU2006328328B2 (es) |
BR (1) | BRPI0620020A2 (es) |
CA (1) | CA2633149C (es) |
CR (1) | CR10032A (es) |
ES (1) | ES2576258T3 (es) |
GE (1) | GEP20115245B (es) |
HR (1) | HRP20160679T1 (es) |
IL (1) | IL191774A0 (es) |
MA (1) | MA30061B1 (es) |
MY (1) | MY149306A (es) |
NO (1) | NO20083104L (es) |
NZ (1) | NZ569071A (es) |
PE (1) | PE20110019A1 (es) |
RU (1) | RU2426530C2 (es) |
TW (1) | TWI384985B (es) |
UA (1) | UA91729C2 (es) |
WO (1) | WO2007072992A2 (es) |
ZA (1) | ZA200805147B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI407959B (zh) | 2006-05-23 | 2013-09-11 | Takeda Pharmaceutical | 口服製劑 |
JP5284968B2 (ja) | 2007-02-01 | 2013-09-11 | 武田薬品工業株式会社 | アログリプチンおよびピオグリタゾンを含有する固形製剤 |
US8367115B2 (en) * | 2007-08-27 | 2013-02-05 | Asahi Kasei Chemicals Corporation | Process for production of crystalline cellulose and tablets containing granules |
MA33056B1 (fr) * | 2009-01-23 | 2012-02-01 | Hanmi Holding Co Ltd | Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication |
ES2739888T3 (es) * | 2009-11-30 | 2020-02-04 | Adare Pharmaceuticals Inc | Composiciones y comprimidos farmacéuticos con recubrimiento compresible y métodos de fabricación |
CN101804056A (zh) * | 2010-04-16 | 2010-08-18 | 山东新华制药股份有限公司 | 盐酸吡格列酮、格列美脲的复方片剂及制备方法 |
JP2013538807A (ja) | 2010-09-01 | 2013-10-17 | ルピン・リミテッド | メトホルミンおよびピオグリタゾンを含む医薬組成物 |
EP2618827B1 (en) * | 2010-09-21 | 2021-06-02 | Intekrin Therapeutics, Inc. | Antidiabetic solid pharmaceutical compositions |
FR2966828B1 (fr) * | 2010-11-02 | 2012-12-28 | Roquette Freres | Poudre de polysaccharide et de polyol, comprimable et de haute viscosite |
WO2013034174A1 (en) | 2011-09-06 | 2013-03-14 | ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. | Solid preparations of pioglitazone and glimepiride |
EP2753309B1 (de) * | 2011-09-08 | 2020-01-01 | Hexal AG | Pharmazeutische zusammensetzung zur oralen darreichung mit einem statin |
PE20141189A1 (es) | 2011-10-21 | 2014-09-24 | Takeda Pharmaceutical | Preparacion de liberacion sostenida |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
CN102641280A (zh) * | 2012-04-23 | 2012-08-22 | 重庆康刻尔制药有限公司 | 一种盐酸吡格列酮格列美脲组合药物、片剂及其应用 |
KR20220070057A (ko) | 2015-03-09 | 2022-05-27 | 인테크린 테라퓨틱스, 아이엔씨. | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
US20160331689A1 (en) * | 2015-05-12 | 2016-11-17 | SE Tylose USA, Inc. | Aqueous enteric coating composition |
KR101782119B1 (ko) * | 2016-02-01 | 2017-10-23 | 주식회사 한독 | 테넬리글립틴 및 설포닐우레아계 약물을 포함하는 정제 |
JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのPPARγアゴニスト |
GB202001237D0 (en) * | 2020-01-29 | 2020-03-11 | Sisteks D O O | Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product |
CN111410687B (zh) * | 2020-02-21 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
CN115721612B (zh) * | 2021-08-26 | 2024-07-26 | 上海宣泰医药科技股份有限公司 | 一种恩扎卢胺固体制剂颗粒及其制备方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3152978B2 (ja) | 1991-12-17 | 2001-04-03 | 塩野義製薬株式会社 | 二層錠およびその製造方法 |
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US5859037A (en) | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
CN1168451C (zh) | 1997-06-18 | 2004-09-29 | 史密丝克莱恩比彻姆有限公司 | 噻唑烷二酮和磺酰脲组合物在制备治疗糖尿病的药物中的用途 |
GB9715306D0 (en) | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
SI1100469T1 (es) * | 1998-07-28 | 2005-08-31 | Takeda Pharmaceutical | |
WO2000028989A1 (en) * | 1998-11-12 | 2000-05-25 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
NZ512663A (en) * | 1999-01-14 | 2004-05-28 | Amylin Pharmaceuticals Inc | Novel exendin agonist formulations and methods of administration thereof |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
AR030920A1 (es) * | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
WO2002030400A1 (fr) | 2000-10-06 | 2002-04-18 | Takeda Chemical Industries, Ltd. | Preparations solides |
JP4284017B2 (ja) * | 2000-10-06 | 2009-06-24 | 武田薬品工業株式会社 | 固形製剤 |
RU2177318C1 (ru) | 2000-12-21 | 2001-12-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция с антидиабетическим действием и способ ее получения |
US20040147584A2 (en) * | 2001-12-05 | 2004-07-29 | Aventis Pharma S.A. | 1,3-diarylprop-2-en-1-ones, compositions containing them and use thereof |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
AU2003281181A1 (en) * | 2002-07-11 | 2004-02-02 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
DE60311821T2 (de) * | 2002-08-30 | 2007-10-31 | Japan Tobacco Inc. | Dibenzylaminverbindung und deren medizinische verwendung |
UA80991C2 (en) * | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
EP1588708A4 (en) * | 2003-01-29 | 2006-03-01 | Takeda Pharmaceutical | METHOD FOR PRODUCING COATED PREPARATION |
US20040147564A1 (en) | 2003-01-29 | 2004-07-29 | Rao Vinay U. | Combinations of glimepiride and the thiazolidinedione for treatment of diabetes |
AU2003282377A1 (en) | 2003-02-05 | 2004-08-30 | Ipca Laboratories Limited | Dual release anti-diabetic drugs and process of production thereof |
WO2004091587A1 (en) * | 2003-04-17 | 2004-10-28 | Ipca Laboratories Limited | Multiple release anti-diabetic drugs and process of production thereof |
TW200510002A (en) | 2003-06-06 | 2005-03-16 | Takeda Chemical Industries Ltd | Solid pharmaceutical preparation |
WO2005000299A1 (en) * | 2003-06-27 | 2005-01-06 | Dr. Reddy's Research Foundation | Compositions comprising balaglitazone and further antidiabetic compounds |
WO2005009407A2 (en) * | 2003-07-29 | 2005-02-03 | Ranbaxy Laboratories Limited | Oral pharmaceutical formulations of olanzapine |
AU2004285354B2 (en) | 2003-10-31 | 2009-09-17 | Takeda Pharmaceutical Company Limited | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
JP4361461B2 (ja) * | 2003-10-31 | 2009-11-11 | 武田薬品工業株式会社 | 固形製剤 |
JP4739189B2 (ja) * | 2004-04-14 | 2011-08-03 | 武田薬品工業株式会社 | 固形製剤 |
WO2005102290A1 (en) * | 2004-04-22 | 2005-11-03 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of a biguanide and a sulfonylurea |
-
2006
- 2006-12-21 RU RU2008130074/15A patent/RU2426530C2/ru not_active IP Right Cessation
- 2006-12-21 AR ARP060105709A patent/AR058605A1/es not_active Application Discontinuation
- 2006-12-21 EP EP06843549.4A patent/EP1962811B1/en active Active
- 2006-12-21 ZA ZA200805147A patent/ZA200805147B/xx unknown
- 2006-12-21 BR BRPI0620020-6A patent/BRPI0620020A2/pt not_active IP Right Cessation
- 2006-12-21 PE PE2010001114A patent/PE20110019A1/es not_active Application Discontinuation
- 2006-12-21 KR KR1020087014632A patent/KR20080080126A/ko active IP Right Grant
- 2006-12-21 NZ NZ569071A patent/NZ569071A/en not_active IP Right Cessation
- 2006-12-21 WO PCT/JP2006/326169 patent/WO2007072992A2/en active Application Filing
- 2006-12-21 AU AU2006328328A patent/AU2006328328B2/en not_active Ceased
- 2006-12-21 ES ES06843549.4T patent/ES2576258T3/es active Active
- 2006-12-21 GE GEAP200610776A patent/GEP20115245B/en unknown
- 2006-12-21 TW TW095148113A patent/TWI384985B/zh not_active IP Right Cessation
- 2006-12-21 CA CA2633149A patent/CA2633149C/en active Active
- 2006-12-21 UA UAA200808310A patent/UA91729C2/ru unknown
- 2006-12-21 US US12/086,700 patent/US8071130B2/en active Active
- 2006-12-21 JP JP2008528691A patent/JP5179363B2/ja active Active
- 2006-12-21 MY MYPI20082251A patent/MY149306A/en unknown
- 2006-12-21 CN CN200680053318.XA patent/CN101384251B/zh active Active
-
2008
- 2008-05-27 IL IL191774A patent/IL191774A0/en unknown
- 2008-05-30 CR CR10032A patent/CR10032A/es not_active Application Discontinuation
- 2008-06-18 MA MA31045A patent/MA30061B1/fr unknown
- 2008-07-10 NO NO20083104A patent/NO20083104L/no not_active Application Discontinuation
-
2016
- 2016-06-14 HR HRP20160679TT patent/HRP20160679T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006328328B2 (en) | 2012-08-30 |
GEP20115245B (en) | 2011-06-27 |
PE20110019A1 (es) | 2011-01-27 |
US20090028939A1 (en) | 2009-01-29 |
EP1962811B1 (en) | 2016-04-27 |
CA2633149A1 (en) | 2007-06-28 |
CN101384251B (zh) | 2014-09-03 |
TWI384985B (zh) | 2013-02-11 |
MY149306A (en) | 2013-08-30 |
BRPI0620020A2 (pt) | 2011-10-25 |
NO20083104L (no) | 2008-09-19 |
CA2633149C (en) | 2015-06-30 |
EP1962811A2 (en) | 2008-09-03 |
CN101384251A (zh) | 2009-03-11 |
IL191774A0 (en) | 2008-12-29 |
US8071130B2 (en) | 2011-12-06 |
RU2008130074A (ru) | 2010-01-27 |
AR058605A1 (es) | 2008-02-13 |
AU2006328328A1 (en) | 2007-06-28 |
HRP20160679T1 (hr) | 2016-07-15 |
KR20080080126A (ko) | 2008-09-02 |
WO2007072992A2 (en) | 2007-06-28 |
TW200731971A (en) | 2007-09-01 |
JP5179363B2 (ja) | 2013-04-10 |
ES2576258T3 (es) | 2016-07-06 |
UA91729C2 (ru) | 2010-08-25 |
RU2426530C2 (ru) | 2011-08-20 |
WO2007072992A3 (en) | 2007-12-06 |
JP2009520681A (ja) | 2009-05-28 |
ZA200805147B (en) | 2010-05-26 |
MA30061B1 (fr) | 2008-12-01 |
NZ569071A (en) | 2011-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10032A (es) | Preparación sólida | |
TW200633716A (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
WO2007061939A3 (en) | Metabolite derivatives of the hdac inhibitor fk228 | |
WO2006091529A3 (en) | A solid pharmaceutical dosage formulation | |
WO2007067044A3 (en) | Modified active-ingredient-containing pellets/capsules | |
NO20071667L (no) | Farmasoytisk preparat omfattende levetiracetam og fremgangsmate for fremstilling av preparatet | |
WO2007127158A3 (en) | Modification of percutaneous absorption of topically active materials | |
MX2010008138A (es) | Forma de dosis farmaceutica. | |
WO2009072007A3 (en) | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof | |
TW200745103A (en) | Substituted 7-azaindazoles, compositions containing them, production process and use | |
BRPI0620229A8 (pt) | formulação | |
WO2008128775A3 (en) | Stabilised pharmaceutical composition containing pregabaline | |
WO2007005941A3 (en) | Liver targeted conjugates | |
MXPA06011467A (es) | Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid). | |
WO2006118884A3 (en) | Drug delivery devices and related components, systems and methods | |
NO20082047L (no) | Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme | |
WO2007090661A3 (en) | Active substance combination comprising azolylcarbinol compounds | |
UY31452A1 (es) | Recubrimiento mejorado de tableta | |
WO2009038095A1 (ja) | セサミン類とビタミンb1類とを配合した組成物 | |
WO2007009691A3 (en) | Combination of substituted pyrazolines and anti -addictive agent | |
WO2009139504A3 (en) | A solid pharmaceutical formulation | |
WO2007009989A3 (de) | ZUSAMMENSETZUNG, DIE EINE LIPOSOMALE DISPERSION VON SIO2-NANOPARTIKELN UND EIN ß-1,3-VERKNÜPFTES GLUCANETHERDERIVAT UMFASST | |
WO2011058336A3 (en) | Tablet comprising gum arabic | |
WO2008041116A3 (en) | Formulations of active principles incorporated in slns suitable for transdermal administration | |
WO2008127283A3 (en) | Engineered metabolic pathways |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal | ||
FC | Refusal |